Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Fluzoparib|DRUG: Apatinib Mesylate|DRUG: Capecitabine tablets|DRUG: Vinorelbine Tartrate Oral|DRUG: Eribulin mesylate injection|DRUG: Gemcitabine Hydrochloride|DRUG: Paclitaxel-albumin
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University